AstraZeneca Pays $25M to License PTX-299 EGFR Degrader, Eyes $500M Milestones
AstraZeneca exercised its option on Pinetree’s PTX-299 EGFR degrader program, triggering a $25 million payment and unlocking up to $500 million in future milestones as it takes over global development and commercialization. The company also published its Q1 2026 earnings call transcript.
1. License Option Exercise and Payment
AstraZeneca has exercised its exclusive licensing option for PTX-299, a bispecific antibody degrader targeting EGFR, under its agreement with Pinetree Therapeutics. The exercise triggers an immediate $25 million payment to Pinetree and grants AstraZeneca responsibility for global development and commercialization, with potential future development, regulatory and commercial milestones exceeding $500 million plus tiered royalties on net sales.
2. Q1 2026 Earnings Call Transcript
On April 29, 2026, AstraZeneca released the full transcript of its Q1 2026 earnings call, providing detailed insights into first-quarter performance, strategic priorities and updates on its oncology and biopharmaceutical pipeline initiatives.